Page last updated: 2024-11-12

gs-9131

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

GS-9131: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44603336
SCHEMBL ID20010574
MeSH IDM0510101

Synonyms (16)

Synonym
gs-9131
ethyl (2s)-2-[[[(2r,5r)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxy-phosphoryl]amino]propanoate
ethyl n-[(r)-({[(2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy}methyl)(phenoxy)phosphoryl]-l-alaninate
SCHEMBL20010574
gs 9131
u8s0ic8dy7 ,
rovafovir etalafenamide [usan]
unii-u8s0ic8dy7
rovafovir etalafenamide
l-alanine, n-((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydro-2-furanyl)oxy)methyl)phenoxyphosphinyl)-, ethyl ester
who 10740
912809-27-9
DB14903
rovafovir etalafenamide [inn]
gs-9148 phosphonoamidate prodrug
DTXSID301336885

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Following oral dosing (3mg/kg) in Beagle dogs, high levels (>9."( Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148.
Birkus, G; Boojamra, CG; Cihlar, T; Desai, MC; Douglas, JL; Gao, Y; Grant, D; Hui, HC; Laflamme, G; Lin, KY; Mackman, RL; Markevitch, DY; McDermott, M; Mishra, R; Pakdaman, R; Petrakovsky, OV; Ray, AS; Vela, JE; Zhang, L, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2 Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus [NCT03472326]Phase 221 participants (Actual)Interventional2018-04-03Terminated(stopped due to GS-9131 did not meet the targeted antiviral response)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03472326 (2) [back to overview]Part 1 Sentinel Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Day 11
NCT03472326 (2) [back to overview]Part 1 Sentinel Cohort 2: Change From Baseline in Plasma log10 HIV-1 RNA at Day 15

Part 1 Sentinel Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Day 11

(NCT03472326)
Timeframe: Baseline, Day 11

Interventionlog10 copies/mL (Mean)
Sentinel Cohort 1: GS-9131 60 mg-0.13

[back to top]

Part 1 Sentinel Cohort 2: Change From Baseline in Plasma log10 HIV-1 RNA at Day 15

(NCT03472326)
Timeframe: Baseline, Day 15

Interventionlog10 copies/mL (Mean)
Sentinel Cohort 2: GS-9131 180 mg-0.29

[back to top]